InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...
Healio

Patients with pyoderma gangrenosum experience higher mortality rates

Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...
Detroit News

Doc: Pyoderma gangrenosum first a blister, then ulcer

Dear Dr. Roach: I am a 74-year-old woman who is in good health. I was diagnosed with pyoderma gangrenosum on my left leg and I was in a lot of pain. Can you tell me the cause of this rare disease?
TipRanks on MSN

InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...